Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

---

Atıf İçin Kopyala

Ulas A., Avci N., Kos T., Cubukcu E., Olmez O. F., Bulut N., ...Daha Fazla

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.20, ss.714-22, 2015 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 20
• Basım Tarihi: 2015
• Dergi Adı: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.714-22
• Anahtar Kelimeler: breast cancer, HER2 positive, lymphocytes, neutrophil, platelet, TUMOR-INFILTRATING LYMPHOCYTES, EPITHELIAL OVARIAN-CANCER, CELL LUNG-CANCER, NEUTROPHIL/LYMPHOCYTE RATIO, PRETREATMENT NEUTROPHIL, GROWTH-FACTOR, COLORECTAL-CANCER, PERIPHERAL-BLOOD, GASTRIC-CANCER, JOINT ANALYSIS
• Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Purpose: To investigate whether the pretreatment neutrophil lymphocyte ratio (NLR) and the platelet lymphocyte ratio (PLR) have any prognostic significance in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab.